The Boeing Company (NYSE:BA) Inks Deal With Iran Air For 80 Aircraft- Quest Diagnostics (NYSE:DGX)

The Boeing Company (NYSE:BA) [Trend Analysis] knocking active thrust in leading trading session, shares a gain of 0.43% to 157.16 with around 4.13 Million shares have changed hands in this session. Boeing (BA) along with Iran Air declared that contract for 80 aircraft that includes 50 737 MAX 8s, 15 777-300ERs and 15 777-9s, valued at $16.6 billion at list prices.Based on its Memorandum of Contract (MOA) with Iran Air reported in June, the contract was reached within the terms of the U.S. Government license issued to Boeing in September.

Boeing said it coordinated closely with the U.S. Government throughout the process leading up to the sale and continues to follow all license requirements as it moves forward to implement the sales contract.’s contract will support tens of thousands of U.S. jobs directly associated with production and delivery of the 777-300ERs and nearly 100,000 U.S. jobs in the U.S. aerospace value stream for the full course of deliveries. The first airplanes under this contract are slated for delivery in 2018, Boeing said. The stock is going forward its fifty-two week low with 57.67% and lagging behind from its 52-week high price with 0.18%.

Similar, the positive performance for the quarter recorded as 22.99% and for the year was 12.34%, while the YTD performance remained at 12.37%. BA has Average True Range for 14 days of 2.38.

Quest Diagnostics Incorporated (NYSE:DGX) [Trend Analysis] retains strong position in active trade, as shares scoring 0.63% to $91.71 in a active trade session, while looking at the shares volume, around 1.31 Million shares have changed hands in this session. Quest Diagnostics Inc. (DGX) declared that it is investigating an unauthorized third-party intrusion into an internet application on its network. On November 26, 2016 an unauthorized third party accessed the MyQuest by Care360 internet application and obtained Protected Health Information or PHI of about 34,000 individuals.

The firm noted that the accessed data included name, date of birth, lab results, and in some instances, telephone numbers. The information did not include Social Security numbers, credit card information, insurance or other financial information. There is no indication that individuals’ information has been misused in any way. The firm has institutional ownership of 91.80%, while insider ownership included 0.10%. DGX attains analyst recommendation of 3.00 with week’s performance of 3.84%. Investors looking further ahead will note that the Price to next year’s EPS is 6.86%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *